Literature DB >> 11153787

Preoperative Multidimensional Affect and Pain Survey (MAPS) scores predict postcolectomy analgesia requirement.

J C Yang1, W C Clark, S L Tsui, K F Ng, S B Clark.   

Abstract

OBJECTIVES: One aim of this study was to evaluate the relation of scores on the Multidimensional Affect and Pain Survey (MAPS) that was administered before surgery to postoperative morphine consumption and patient-controlled analgesia. A second aim of the study was to compare the ability of MAPS administered postsurgery with the commonly used Numerical Pain Rating Scale to predict patient-controlled analgesia behavior.
DESIGN: The MAPS questionnaire measures pain, suffering, and well-being. It was administered to patients 1 day before and 1 day after left hemicolectomy for colon cancer. The relations of the two scores to postoperative pain control were determined. PATIENTS: Thirty-four patients in the surgical ward of a general hospital admitted for colorectal cancer surgery participated in this study.
RESULTS: High preoperative MAPS scores on sensory and emotional words predicted postoperative morphine dosage, dose presses, and lockout presses. Greater morphine consumption was correlated positively with high presurgery MAPS scores in four of the eight "Suffering" subclusters (Depressed Mood, Anger, Anxiety, and Fear). High presurgery MAPS scores in 13 of the 17 "Sensory Qualities" subclusters (e.g., Bothersome, Intense Pain, Pain Extent, Incisive Pressure, Traction/Abrasion) were correlated positively with lockout presses. Neither the postsurgery MAPS nor the postsurgery Numerical Pain Rating Scale predicted patient-controlled analgesia behavior.
CONCLUSION: The emotional states and attitudes of the patients toward pain before surgery are important factors in determining patient-controlled analgesia pressing behavior and postoperative demand for analgesics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153787     DOI: 10.1097/00002508-200012000-00007

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  6 in total

1.  The pharmacogenetics of codeine pain relief in the postpartum period.

Authors:  M Baber; S Chaudhry; L Kelly; C Ross; B Carleton; H Berger; G Koren
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

2.  The effects of exergaming on pain, postural control, technology acceptance and flow experience in older people with chronic musculoskeletal pain: a randomised controlled trial.

Authors:  Jae-Llane Ditchburn; Paul van Schaik; John Dixon; Alasdair MacSween; Denis Martin
Journal:  BMC Sports Sci Med Rehabil       Date:  2020-10-09

3.  Sources of anticipatory distress among breast surgery patients.

Authors:  Guy H Montgomery; Daniel David; Alisan B Goldfarb; Jeffrey H Silverstein; Christina R Weltz; Jennifer S Birk; Dana H Bovbjerg
Journal:  J Behav Med       Date:  2003-04

4.  Remifentanil consumption in septoplasty surgery under general anesthesia. Association with humane mu-opioid receptor gene variants.

Authors:  Mahmoud M Al-Mustafa; Abdelkarim S Al Oweidi; Khaled R Al-Zaben; Ibraheem Y Qudaisat; Sami A Abu-Halaweh; Subhi M Al-Ghanem; Islam M Massad; Walid K Samarah; Reem A Al-Shaer; Said I Ismail
Journal:  Saudi Med J       Date:  2017-02       Impact factor: 1.484

5.  Biological inflammatory markers mediate the effect of preoperative pain-related behaviours on postoperative analgesics requirements.

Authors:  Myriam Daoudia; Céline Decruynaere; Bernard Le Polain de Waroux; Jean-Louis Thonnard; Léon Plaghki; Patrice Forget
Journal:  BMC Anesthesiol       Date:  2015-12-16       Impact factor: 2.217

6.  A systematic review of the risk factors for clinical response to opioids for all-age patients with cancer-related pain and presentation of the paediatric STOP pain study.

Authors:  Ersilia Lucenteforte; Laura Vagnoli; Alessandra Pugi; Giada Crescioli; Niccolò Lombardi; Roberto Bonaiuti; Maurizio Aricò; Sabrina Giglio; Andrea Messeri; Alessandro Mugelli; Alfredo Vannacci; Valentina Maggini
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.